Brief news reports on Tuberculosis

SOUTH AFRICA: Shortage of drug-resistant TB treatment looms

JOHANNESBURG, 16 August 2011 (PlusNews) - While countries are rolling out new tests that will enable them to diagnose more patients with drug-resistant tuberculosis (DR-TB), a worldwide shortage of the drugs to treat these patients is likely, Médecins Sans Frontières (MSF) warns.

Read More →

SOUTH AFRICA: Govt moves to earlier HIV treatment

JOHANNESBURG, 15 August 2011 (PlusNews) - HIV-positive people in South Africa will be able to access antiretrovirals (ARVs) sooner after the government raised the CD4 count necessary to access treatment. But some warn the victory is only half the battle.

Read More →

Round 11 Global Fund launch: Let's make it a TB round!

15 August 2011 - Geneva - Today is a very important day for all people committed to making tuberculosis (TB) care available to all who need it.

Read More →

Bayer donates drugs to help stamp out tuberculosis

Bayer has said it will donate 620,000 tablets of its antibiotic moxifloxacin in order to help tackle multi-drug resistant tuberculosis.

Read More →

Researchers discover key reason why pyrazinamide shortens duration of TB therapy

Pyrazinamide has been used in combination with other drugs as a first-line treatment for people with tuberculosis (TB) since the 1950s, but exactly how the drug works has not been well understood. Now, researchers have discovered a key reason why the drug effectively shortens the required duration of TB therapy. The finding potentially paves the way for the development of new drugs that can help eliminate TB in an infected individual even more rapidly. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and published online on August 11 in Science Express.

Read More →

Cepheid fares well with sales of rapid TB test in developing countries

Producer of the rapid TB diagnostic GeneXpert, Cepheid recently announced its 2011 second quarter profits in an earnings report and subsequent public conference call. Revenues for the quarter reached $67 million, an increase of 11 percent from the previous quarter and 35 percent from the second quarter of 2010. Cepheid is now projecting revenues of $265 to $270 million for all of 2011, $15 to $20 million above its previous projections.

Read More →

New tuberculosis vaccine enters Phase IIb proof-of-concept trial in people living with HIV in Senegal and South Africa

ROCKVILLE, MD, USA/LONDON, UK, August 11, 2011 – Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus (HIV). The trial will be conducted at research sites in Senegal and South Africa with primary funding support from the European and Developing Countries Clinical Trials Partnership (EDCTP).

Read More →

Research on TB tests prompts first-ever WHO negative policy

No policy has ever recommended serological (antibody) tests to detect active tuberculosis (TB) yet dozens of these blood tests are currently marketed and sold in developing countries where regulation is weak or non-existent. More than a million of these unapproved tests are carried out every year, usually at a high cost – financial and human – to unsuspecting patients. Mounting evidence clearly shows that the tests do not accurately diagnose TB – they often cause false-positives and false-negatives – and they are not as cost effective as other recommended TB tests.

Read More →

U.S. delegation in South Africa to renew bilateral relationship, create sustainable partnerships in health

This post on the Center for Strategic and International Studies (CSIS)'s Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."

Read More →

Immune Network to start clinical trial of Đ¾ral mycobacterium vaccae in tuberculosis patients

VANCOUVER, British Columbia, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Immune Network Ltd. reports that its business partner Immunitor company has launched a Phase 2 clinical trial of a novel anti-tuberculosis immunotherapy consisting of orally-delivered, heat-inactivated Mycobacterium vaccae. The new tableted preparation was formulated according to clinically validated proprietary technology developed by Immunitor company.

Read More →

Page 750 of 751 · Total posts: 10

←First 749 750 751 Last→